Content available at: https://www.ipinnovative.com/open-access-journals

IP International Journal of Ocular Oncology and Oculoplasty

Journal homepage: https://www.ijooo.org/

Review Article

Pediatric ocular tumors: Current perspectives and future directions

Pankaj Khuspe[1]*, Swapnil Phade[1], Sakshi Kakade[1], Prajakta Inamdar[1], Kishori Kokate[2]

[1]Dept. of Pharmaceutics, Shriram Shikshan Sanstha's College of Pharmacy, Paniv, Maharashtra, India
[2]Devdikar Medical Centre and Reseach, Akluj, Maharashtra, India

Abstract

Retinoblastoma is the most common intraocular cancer among pediatric ocular malignancies, which include a wide range of benign and malignant neoplasms that impact children's ocular and periocular structures. Because of their rarity, histological heterogeneity, possibility for visual loss, and potential for life-threatening metastases, these tumors present considerable diagnostic and treatment problems. Particularly for retinoblastoma, where intra-arterial and intravitreal chemotherapy, in conjunction with focused therapies, have revolutionized management paradigms, developments in molecular genetics, imaging technologies, and therapeutic approaches have significantly improved results. Despite these developments, multidisciplinary care and close monitoring are still required due to long-term morbidity, the possibility of developing second primary cancers, and genetic implications. Precision medicine techniques, such as the creation of tailored treatments and immunotherapeutic tactics, have been made possible by new discoveries on the molecular and cellular pathophysiology of ocular malignancies. There is potential for early identification, risk assessment, and individualized treatment plans with the combination of genetic profiling and biomarker-driven diagnostics. Furthermore, advances in imaging methods, such new MRI protocols and optical coherence tomography, have improved diagnostic precision and less invasively monitored therapeutic response. In order to clarify tumor biology, find new therapeutic targets, and create less harmful, vision-preserving treatments, future directions highlight the necessity of cooperative research. International registries and pediatric-specific clinical trials are crucial for producing solid evidence to direct practice. Furthermore, using artificial intelligence in predictive modeling and image analysis could improve diagnosis and treatment even more. Improving patient outcomes and quality of life requires a thorough understanding of pediatric ocular malignancies, bolstered by translational research and technological innovation.

Keywords: Pediatric ocular tumors, Retinoblastoma, Targeted therapy, Molecular diagnostics, Vision-sparing treatments.

Received: 19-05-2025; **Accepted:** 23-07-2025; **Available Online**: 11-08-2025

1. Introduction

1.1. Definition and clinical significance

A diverse set of neoplasms that impact the globe, orbit, and ocular adnexa throughout childhood are known as pediatric ocular tumors. These tumors might be benign, self-limiting lesions or malignant cancers that have the ability to spread throughout the body, cause local invasion, and impair eyesight. Pediatric variations of ocular malignancies frequently have different biological behaviors and genetic profiles than adult versions, which calls for specific diagnostic and treatment strategies. In terms of tumor care, the eye's distinct architecture and immune-privileged position offer both opportunities and obstacles. Because the visual system develops dynamically in infants, maintaining visual function is very important. In addition to being an oncologic problem, pediatric ocular tumors pose developmental and psychological issues that may have long-term effects on quality of life. The common pediatric ocular tumors are enlisted in **Table 1**.[1]

1.2. Overview of tumor types

Based on their anatomical location, pediatric ocular cancers are usually divided into three categories: intraocular, orbital, and adnexal. With the majority of cases occurring in children under five, retinoblastoma is the most common and well-researched of the intraocular cancers. Even though they are very uncommon in pediatric populations, uveal melanoma and medulloepithelioma, a rare ciliary body tumor, also need clinical care. Proptosis or ocular misalignment are common

*Corresponding author: Pankaj Khuspe
Email: khuspepankaj@gmail.com

http://doi.org/10.18231/j.ijooo.v.11.i.2.5

symptoms of orbital cancers like rhabdomyosarcoma, the most common soft tissue sarcoma in children, and benign lesions such capillary hemangiomas and dermoid cysts. Although they are less common, adnexal cancers, which include sebaceous gland carcinoma and lymphangioma, can affect the eyelid or lacrimal gland. Every form of tumor exhibits distinct clinical and histological traits, which emphasizes the necessity of customized treatment plans and diagnostic processes.[2,3]

1.3. Importance of early diagnosis and treatment

For juvenile ocular malignancies, early identification and prompt treatments are essential to improving results. In malignant situations such orbital rhabdomyosarcoma or advanced retinoblastoma, a delayed diagnosis can lead to increased morbidity, irreversible visual impairment, or even death. Additionally, treatments that preserve binocular vision and prevent amblyopia in developing children are frequently made possible by early-stage disease. The combination of genetic screening, minimally invasive treatment methods, and modern imaging modalities has improved therapeutic safety and diagnostic accuracy. Early identification is still hampered by differences in tumor awareness and healthcare access, especially in regions with minimal resources. Therefore, it is still crucial to prioritize newborn screening procedures, parent education, and early referral mechanisms. In this review, we offer a thorough analysis of the state of knowledge about pediatric ocular malignancies, looking at both long-standing paradigms and new developments in diagnosis, therapy, and future research avenues.[4,5]

2. Epidemiology and Classification

2.1. Incidence and prevalence

Despite being comparatively uncommon in the general population, pediatric ocular cancers affect vision, ocular anatomy, and even survival, making them a clinically relevant category of juvenile malignancies. Retinoblastoma is the most prevalent intraocular cancer in children, making up to 3% of all childhood malignancies and occurring in 1 in every 15,000 to 20,000 live births worldwide. Although there is no regional variation in its occurrence, diagnostic and healthcare discrepancies may cause underreporting in low-resource settings. With an estimated occurrence of 0.4 per million children per year, orbital tumors, including rhabdomyosarcoma, are the most common primary orbital malignancies in the pediatric population. Although they usually represent less of a risk to life or vision, benign tumors such as dermoid cysts and capillary hemangiomas are more prevalent overall and frequently appear within the first year of life. Given that delayed diagnosis in underfunded healthcare systems frequently results in advanced disease at presentation, especially in malignant instances like retinoblastoma, epidemiological data highlight the significance of region-specific investigations.[6]

2.2. Classification by location and histology

Based on their histological characteristics and anatomical location of origin, pediatric ocular cancers are categorized. Tumors can be classified anatomically as intraocular (found inside the globe), orbital (found in the soft tissues surrounding the eye), or ocular adnexal (found in the eyelids, conjunctiva, or lacrimal system). Histologically, tumors can be classified as either benign or malignant, and they can also be further subdivided into vascular, mesenchymal, neuroectodermal, or epithelial tissues. Retinoblastoma is the archetypal example of an intraocular cancer, frequently caused by biallelic inactivation of the RB1 tumor suppressor gene. The nonpigmentedciliary epithelium gives rise to uncommon intraocular malignancies such medulloepithelioma, which can behave aggressively. Rhabdomyosarcoma develops in the orbit from primitive mesenchymal cells and often first resembles benign inflammatory conditions. Although histologically benign, ocular adnexal tumors such capillary hemangiomas or epidermoid cysts can cause ocular anatomical distortion and vision impairment if left untreated. Accurate diagnosis, risk assessment, and treatment planning are made easier by a single classification system that combines clinical, radiographic, and histological criteria. In pediatric populations, where maintaining visual function and reducing treatment-related morbidity are critical, this segmentation is particularly important.[7]

3. Clinical Presentation

The anatomical origin, histology, and rate of advancement of juvenile ocular malignancies are frequently correlated with the tumor's many clinical symptoms. The visual prognosis and overall survival are greatly impacted by early care, which requires prompt identification of distinctive indications and symptoms.[7]

3.1. Retinoblastoma

The most common primary intraocular cancer in children is retinablastoma, which is usually identified before the age of five. It frequently manifests as strabismus, which indicates retinal involvement, and leukocoria, a white pupillary reaction that is frequently observed in flash photography. In more severe cases, symptoms could include proptosis in extraocular extension, orbital cellulitis-like symptoms, uveitis, or buphthalmos. Genetic counseling is necessary since bilateral illness frequently signifies a germline RB1 mutation. Treatment becomes more difficult and the chance of recurrence increases when intraocular tumor spread results in vitreous and subretinal seeding.[8,9]

3.2. Rhabdomyosarcoma

The most prevalent soft-tissue orbital sarcoma in children, rhabdomyosarcoma, usually manifests initially as conjunctivalchemosis, eyelid enlargement, and unilateral proptosis that develops quickly. The most common affected

orbit is the superior orbit, and symptoms can resemble those of orbital cellulitis. Rapid biopsies and imaging are frequently required due to tumor aggressiveness in order to direct multimodal therapy. Compared to the alveolar variety, the embryonal subtype is more common in pediatric patients and typically indicates a better prognosis.[10]

3.3. Medulloepithelioma

Early infancy is usually when medulloepithelioma, an uncommon intraocular tumor originating from the non-pigmented ciliary epithelium, is identified. Patients may appear with apparent anterior segment masses, ocular discomfort, or blurred vision, but the clinical symptoms are frequently mild and nonspecific. Diagnosis may be delayed by secondary symptoms such hyphema, uveitis, or neovascular glaucoma. There are both benign and malignant varieties, and the tumor may show solid or cystic characteristics on imaging. After enucleation or surgical excision, histopathologic confirmation is frequently required.[11]

3.4. Ocular melanoma

Ocular melanoma, which is extremely uncommon in children, can develop in the choroid, conjunctiva, or uveal tract and is frequently linked to predisposing factors such as ocular or oculodermalmelanocytosis. Depending on size and location, symptoms can include impaired vision, photopsia, or abnormalities in the visual field. A pigmented, dome-shaped lesion with a potential orange lipofuscin layer is usually seen upon fundoscopic inspection. Using imaging and biopsy, pediatric instances must be carefully differentiated from melanocytoma or other pigmented lesions.[12]

3.5. Benign tumors: Dermoid cysts and hemangiomas

Despite not being life-threatening, benign orbital tumors have the potential to significantly alter ocular anatomy. Dermoid cysts are slow-growing, painless, well-circumscribed lumps that are visible in infancy or early childhood. They are typically seen at the superotemporal orbital rim. Localized pain and discomfort can result from inflammation or rupture. The most prevalent vascular orbital tumor in babies, capillary hemangiomas, on the other hand, can cause eyelid swelling, ptosis, or proptosis soon after delivery. While deep lesions might impair visual development by causing amblyopia or astigmatism, superficial versions manifest as brilliant red lesions on the eyelid or conjunctiva. The majority go away on their own, while larger or more cosmetically dangerous lesions can need medication or surgery.[13]

4. Diagnostic Approaches

For juvenile ocular malignancies to be effectively managed and to have a favorable prognosis, prompt and accurate diagnosis is essential. To determine the type, extent, and underlying cause of the tumor, the diagnostic approach combines genomic and genetic testing with sophisticated imaging modalities. In addition to helping distinguish benign from malignant lesions, multimodal diagnostic technologies make treatment planning and therapeutic response monitoring easier. The diagnostic tools and their utility are enlisted in **Table 2**.[13,14]

4.1. Imaging techniques

4.1.1. Ultrasound B-scan

When evaluating intraocular malignancies, ultrasound B-scan is still essential, particularly in situations with limited resources or when direct visualization is impeded by media opacities. Characteristics like intra-lesional calcifications, which are pathognomonic for retinoblastoma, can be detected with this non-invasive technique. It is essential for initial evaluation and serial monitoring due to its capacity to define tumor size, internal reflectivity, and posterior expansion.[16]

4.1.2. Magnetic resonance imaging (MRI) and computed tomography (CT)

MRI is the preferred modality for evaluating orbital extension, optic nerve involvement, and intracranial dissemination, especially in trilateral retinoblastoma, due to its superior soft tissue contrast resolution and multiplanar imaging capabilities. Gadolinium-contrast T1- and T2-weighted sequences improve the ability to distinguish tumor borders and surrounding anatomical features. Despite becoming less popular because of ionizing radiation, CT imaging is nevertheless helpful for assessing osseous orbital involvement and detecting calcification patterns in intraocular tumors.[17]

4.1.3. Optical coherence tomography (OCT) and fundus imaging

Particularly in situations of tiny or regressed retinoblastoma, high-resolution cross-sectional imaging with OCT is essential for identifying retinal disarray, subretinal fluid, and early tumor growth. The use of handheld OCT devices has increased while dealing with recalcitrant pediatric anesthetists. Frequently carried out under general anesthesia, fundus photography records lesion morphology, vasculature, and development, especially in longitudinal follow-up, and so enhances clinical assessment.[18]

4.2. Molecular diagnostics

4.2.1. RB1 gene mutation analysis

The main biological causes of retinoblastoma are germline and somatic mutations in the RB1 tumor suppressor gene. Molecular genetic testing provides a conclusive diagnosis, especially in cases that are bilateral or familial, and helps guide genetic counseling and surveillance plans. Finding particular mutation types may also help with risk stratification by correlating with laterality and disease severity.[19]

4.2.2. Liquid biopsy

Cutting-edge methods like aqueous humor liquid biopsy, which provide a less invasive option to traditional tissue sample, have demonstrated promise in the detection of tumor-derived cell-free DNA. Personalized therapeutic interventions are made possible by these methods, which enable real-time molecular profiling, tumor burden assessment, and the identification of high-risk genetic changes.[20]

4.2.3. Immunohistochemistry (IHC)

In the histopathologic assessment of removed orbital and ocular malignancies, IHC is a useful supplementary tool. It is easier to distinguish between distinct tumor forms, including lymphoma, medulloepithelioma, and rhabdomyosarcoma, when lineage-specific markers are expressed. Additionally, IHC can identify treatment targets and prognostic biomarkers, which is consistent with precision oncology paradigms.[21]

Table 1: Common pediatric ocular tumors[1]

Tumor Type	Anatomical Location	Histology	Nature	Relative Frequency
Retinoblastoma	Intraocular	Neuroectodermal	Malignant	Most common intraocular
Rhabdomyosarcoma	Orbit	Mesenchymal	Malignant	Most common orbital tumor
Medulloepithelioma	Ciliary body	Neuroepithelial	Malignant	Rare
Capillary Hemangioma	Orbit / Eyelid	Vascular	Benign	Common in infancy
Dermoid Cyst	Orbit / Adnexa	Epithelial	Benign	Frequently encountered
Conjunctival Melanoma	Ocular surface	Melanocytic	Malignant	Extremely rare in children
Optic Nerve Glioma	Intraorbital / Intracanalicular	Glial tissue	Benign (low-grade)	Associated with NF1

Table 2: Diagnostic tools and their utility[16]

Diagnostic Tool	Utility	Tumor Types	Advantages
Ultrasound B-scan	Detects intraocular masses, calcifications	Retinoblastoma, Medulloepithelioma, Hemangiomas	Non-invasive, cost-effective, provides real-time results
Magnetic Resonance Imaging (MRI)	Detailed soft tissue contrast, detects orbital involvement	Retinoblastoma, Orbital Rhabdomyosarcoma, Medulloepithelioma	High-resolution images, useful for tumor staging
Optical Coherence Tomography (OCT)	High-resolution imaging of retinal structures	Retinoblastoma, Retinal tumors	Non-invasive, real-time imaging, sensitive to early tumor changes
Fluorescein Angiography	Assesses retinal and choroidal vascular changes	Retinoblastoma, Ocular Melanoma	Provides functional information about retinal circulation
Fundus Photography	Document retinal changes and tumor morphology	Retinoblastoma, Retinal Hemangioma	Widely accessible, useful for monitoring tumor progression
Genetic Testing (RB1 Mutation Analysis)	Identifies genetic mutations (e.g., RB1)	Retinoblastoma	Crucial for diagnosis, genetic counseling, and treatment planning
Computed Tomography (CT)	Detects orbital masses and calcification	Orbital Rhabdomyosarcoma, Ocular Melanoma	Good for bone involvement, fast and widely available

Table 3: Treatment modalities overview with location[22]

Treatment Modality	Location	Utility	Tumor Types	Advantages
Enucleation	Intraocular (Retina)	Removal of the affected eye in advanced cases	Retinoblastoma, Medulloepithelioma	Effective for advanced disease, prevents metastasis
Chemotherapy (Systemic, Intra-arterial)	Systemic/Arterial	Systemic or targeted chemotherapy to shrink tumors	Retinoblastoma, Orbital Rhabdomyosarcoma	Can treat systemic spread, reduces tumor size for focal therapies
Intravitreal Chemotherapy	Intraocular (Vitreous)	Direct injection into the eye for localized treatment	Retinoblastoma	Vision-preserving, reduces systemic side effects

Laser Photocoagulation	Intraocular	Focal treatment using laser to ablate tumor cells	Retinoblastoma	Minimally invasive, preserves vision
Cryotherapy	Intraocular/Periocular	Freezing therapy to destroy tumor tissue	Retinoblastoma, Retinal Hemangiomas	Minimally invasive, effective for small tumors
Radiotherapy (Proton Beam, Plaque Brachytherapy)	Intraocular/Orbital	Targeted radiation therapy	Retinoblastoma, Orbital Rhabdomyosarcoma	Precise targeting, minimizes collateral damage
Surgical Resection	Orbit/ Periorbital	Surgical removal of orbital masses and tumors	Orbital Rhabdomyosarcoma, Medulloepithelioma	Effective for localized tumors, preserves function
Immunotherapy	Systemic	Enhances immune system to fight tumors	Retinoblastoma, Ocular Melanoma	Emerging therapy, potential for personalized treatment

5. Current Treatment Modalities

The current treatment modalities overview with location are enlisted in **Table 3**.[22]

5.1. Retinoblastoma

Over the past 20 years, the care of retinablastoma has changed from mostly surgical methods to multidisciplinary techniques that focus on globe salvage, vision preservation, and minimizing systemic toxicity. The tumor's stage, laterality, and patient-specific characteristics all have a significant role in the therapeutic approach chosen.[23]

5.1.1. Enucleation

For advanced intraocular retinoblastoma, enucleation is still the only effective treatment, especially when Group E disease is present or the visual prognosis is considered poor. When tumor-associated retinal detachment, vitreous hemorrhage, or neovascular glaucoma prevent visual recovery, this surgery is frequently recommended. After enucleation, histopathological analysis offers important prognostic information, especially with regard to high-risk characteristics including scleral extension, optic nerve infiltration, and choroidal invasion.[24]

5.1.2. Systemic and Intra-arterial chemotherapy

Systemic chemotherapy has long been a mainstay of conservative treatment, usually consisting of vincristine, etoposide, and carboplatin (VEC regimen). It works well to lessen tumor burden so that focal therapy can be used later. Chemotherapeutic chemicals are directly administered to the ocular artery under fluoroscopic guidance in intra-arterial chemotherapy (IAC), a highly targeted technique that has gained popularity recently. This method has shown encouraging globe salvage rates, especially in unilateral and refractory cases, and dramatically increases medication concentration in the eye while limiting systemic exposure.[25]

5.1.3. Intravitreal chemotherapy

The treatment of vitreous seeding, a historically difficult aspect of retinoblastoma, has greatly improved with the advent of intravitreal chemotherapy, most frequently melphalan. Intravitreal therapy has been established as a dependable adjunct in multimodal treatment regimens by reducing the risks of extraocular dissemination by meticulous injection protocols using safety-enhancing techniques, such as triple-freeze cryotherapy at the injection site.[26]

5.1.4. Focal therapies

Laser photocoagulation, cryotherapy, and thermotherapy are examples of focal treatments that are crucial for the treatment of small to medium-sized tumors and for consolidation after chemoreduction. When used on lesions that are distant from the macula and optic disc, these modalities are especially helpful in maintaining vision. Among these, transpupillary thermotherapy (TTT) is appropriate for posterior pole malignancies due to its deeper tissue penetration.[23]

5.1.5. Radiotherapy

Although external beam radiation therapy (EBRT) has become less common because of its link to secondary cancers and poor orbital development in carriers of germline RB1 mutations, it is still an option in some situations. Plaque brachytherapy, which uses iodine-125 or ruthenium-106 isotopes, is especially helpful for posterior segment cancers or focal recurrences since it delivers radiation locally with less systemic effect. With its limited exit dose and accurate dose distribution, proton beam treatment has gained popularity as a safer substitute for EBRT, especially for tumors close to important eye structures.[27]

5.2. Orbital tumors

The treatment of orbital cancers in children is very tumor-specific and frequently calls for a multidisciplinary team that includes radiation oncologists, pediatric oncologists, and ophthalmologists. Orbital rhabdomyosarcoma, a malignant

soft tissue sarcoma that usually manifests in early childhood, is one of the most common.[28]

5.2.1. Chemotherapy protocols (e.g., VAC for Rhabdomyosarcoma)

For orbital rhabdomyosarcoma, the VAC regimen which consists of vincristine, actinomycin-D, and cyclophosphamide continues to be the accepted frontline chemotherapy. Chemotherapy is the foundation of treatment because it effectively reduces cytotoxicity and makes supplementary modalities possible. According to the Intergroup Rhabdomyosarcoma Study (IRS) guidelines, tumor stage and histologic subtype may serve as a reference for dose adjustments and protocol alterations.[29]

5.2.2. Surgical resection

Due to anatomical limitations and the possibility of functional restriction, surgical excision plays a variable role in orbital tumors and is typically saved for biopsy or debulking rather than total resection. Complete excision may be curative in cases of benign lesions or limited neoplasms with clearly defined margins. Surgery is usually only performed on malignant tumors that are not responsive to chemoradiation or that still have illness after treatment.[30]

5.2.3. Radiotherapy

For the treatment of orbital rhabdomyosarcoma and other radiosensitive cancers, radiotherapy is an essential adjuvant. High doses of radiation can be delivered while protecting nearby healthy tissues thanks to contemporary radiation treatments like proton therapy and intensity-modulated radiation therapy (IMRT). In order to improve local control and avoid recurrence, radiation is usually administered after chemotherapy, particularly in cases where there is a residual tumor.[31]

6. Emerging and Future Therapies

6.1. Targeted therapy

The creation of targeted medicines that interfere with particular pathways linked to the etiology of juvenile ocular tumors has been made easier by recent developments in molecular oncology. The deregulation of the RB1 gene and related cell cycle regulators in retinoblastoma has made it possible to specifically block downstream effectors such MDM2, CDK4/6, and MYCN. Preclinical and early clinical testing is being done on small-molecule inhibitors that target these pathways in an effort to reduce systemic toxicity and achieve tumor regression. Tyrosine kinase inhibitors and anti-angiogenic drugs delivered specifically to the ocular compartment have demonstrated promise in lowering the intraocular tumor burden, particularly in instances that are refractory or have relapsed.[32,33]

6.2. Immunotherapy

Immunotherapeutic approaches are becoming more popular in pediatric ocular oncology as supplemental or substitute therapies. Although they have been thoroughly examined in adult cancers, checkpoint inhibitors that target PD-1/PD-L1 and CTLA-4 are currently being investigated for their potential use in pediatric tumors with immunogenic characteristics, such as advanced retinoblastoma and ocular melanoma. Additionally, adoptive cellular therapies have shown strong cytotoxic effect in preclinical models, such as T-cell receptor-engineered lymphocytes and CAR-T cells that are selective for tumor-associated antigens. In order to induce long-lasting immunological memory and decrease recurrence, vaccine-based immunotherapy that targets retinoblastoma-specific neoantigens is also being investigated.[34]

6.3. Gene therapy

The treatment of genetic ocular cancers, especially retinoblastoma, which results from biallelic inactivation of the RB1 tumor suppressor gene, is at the forefront of gene therapy. Viral vectors, like adeno-associated viruses (AAV), are used in current methods to either modify downstream carcinogenic pathways or reinstall functional RB1. CRISPR-Cas9-mediated genome editing is one of the parallel techniques used to fix germline or somatic mutations that cause cancer. Gene therapy, which represents a paradigm change from tumor-targeting to gene correction, offers the possibility of disease alteration at the molecular level, but it is currently in the experimental stage.[35]

6.4. Nanotechnology-based delivery

Because of the distinct physiological and anatomical barriers of the eye, nanomedicine is becoming a radical method for drug administration in ocular cancers. Liposomes, dendrimers, and polymeric micelles are examples of nanoparticle-based carriers that have been developed to enable the targeted, prolonged, and minimally invasive delivery of biologics and chemotherapeutics. Drug-loaded nanoparticles administered intraocularly have shown increased tumor penetration, decreased systemic exposure, and improved bioavailability in retinoblastoma. Theranostics multifunctional nanocarriers that can perform both imaging and therapy at the same time is being investigated to allow for real-time therapeutic response monitoring.[36]

6.5. Artificial intelligence in diagnosis and treatment planning

With its powerful tools for diagnosis, prognostication, and individualized therapy planning, artificial intelligence (AI) is gradually making its way into pediatric ocular oncology. With high sensitivity and specificity, machine learning algorithms trained on big datasets including fundus photos, MRI scans, and ultrasonography can help detect intraocular malignancies early. AI-powered systems can also

recommend the best course of treatment, forecast therapeutic results, and stratify patients according to risk profiles. Identifying benign from malignant lesions, lowering diagnostic mistakes, and enhancing clinical decision-making in challenging situations are all made possible by AI-based image analysis.[37]

7. Prognosis and Outcomes

The type of tumor, the time of diagnosis, and the treatment methods used all have a significant impact on the prognosis for juvenile ocular malignancies. Thanks to developments in targeted therapy, molecular profiling, and early identification, survival rates and visual preservation have greatly increased. There are still difficulties, though, especially with aggressive and uncommon malignancies where results might differ greatly.[38]

7.1. Survival rates by tumor type

The histological characteristics of the tumor and the stage at diagnosis have a significant impact on survival outcomes in juvenile ocular malignancies. Modern treatments like intra-arterial chemotherapy and focused therapy give great survival prospects for retinoblastoma, the most prevalent intraocular tumor, with survival rates exceeding 95% in developed nations when discovered early and treated effectively. Although localized retinoblastoma has a 98% 5-year survival rate, metastases can drastically reduce survival rates. Depending on the severity of the disease at diagnosis, orbital rhabdomyosarcoma has a more variable prognosis, with overall survival rates varying from 50% to 80%. Despite being exceedingly uncommon in children, ocular melanoma often has a worse prognosis, with 5-year survival rates ranging from 60 to 80%, depending on the tumor's size, location, and potential for metastasis.[39]

7.2. Vision preservation statistics

One of the main objectives of treating pediatric ocular malignancies, particularly retinoblastoma and other intraocular neoplasms, is to preserve vision. Thanks to developments in targeted treatments, chemotherapy, and the prudent use of radiation, it is becoming more and more possible to preserve eyesight in patients with retinoblastoma. According to studies, after receiving contemporary treatments, 70–80% of children with unilateral retinoblastoma are able to maintain useful eyesight, whereas bilateral instances require more sophisticated management techniques. Vision preservation for orbital rhabdomyosarcoma is frequently subsequent to life-saving treatment, with radiation or surgical resection affecting the visual result. On the other hand, sight can frequently be preserved with less aggressive cancers, particularly when the tumor's location allows for conservative measures. Vision loss is more common with ocular melanoma, and in cases with significant tumor load, enucleation is often the recommended course of treatment. Despite these obstacles, results are still becoming better thanks to continuous research into less intrusive and vision-preserving procedures.[33]

7.3. Long-term follow-up needs

For children who have survived ocular tumors, long-term follow-up care is essential to track for recurrence, secondary cancers, and side effects from treatment. Later in life, children who got radiation treatment for retinoblastoma are more likely to develop additional malignancies, such as melanomas and sarcomas. Therefore, it is advised to have lifelong surveillance for subsequent cancers. Survivors of childhood ocular malignancies may have serious psychosocial difficulties in addition to cancer recurrence, such as the psychological effects of vision loss or disfigurement, which can lower quality of life. Long-term treatment must include genetic counseling, imaging studies, and routine eye checks. To offer comprehensive care that meets these patients' medical and emotional requirements, pediatric oncologists must work closely with ophthalmologists, geneticists, and psychologists. Even though juvenile ocular tumor survival rates have considerably increased, the prognosis is complex and requires customized treatment regimens as well as careful long-term monitoring. Optimizing results, protecting vision, and guaranteeing the general health of pediatric patients all depend on early diagnosis, cutting-edge treatments, and strong post-treatment monitoring systems.[40]

8. Challenges and Gaps

8.1. Late diagnosis in low-resource settings

Late diagnosis is one of the biggest obstacles to treating juvenile ocular malignancies, especially in settings with limited resources. These areas frequently lack access to specialized pediatric eye care and sophisticated diagnostic tools like high-resolution imaging methods (like OCT or MRI). Delays in seeking medical attention are also frequently caused by cultural barriers and a lack of knowledge about the symptoms of ocular malignancies, such as leukocoria in retinoblastoma. As a result, the prognosis is worse and many children present at advanced stages of the condition, when treatment options are restricted. The quality of life of impacted children is greatly impacted by the loss of vision and decreased survival rates that result from the failure to provide prompt therapies. The management of juvenile ocular malignancies in these settings is made more difficult by the difficulty of delayed diagnosis and inadequate follow-up care.[41]

8.2. Limited pediatric clinical trials

The paucity of pediatric clinical trials represents another significant gap in the treatment of children eye malignancies. Due to their relative rarity, pediatric cancers including ocular tumors make it challenging to gather sizable cohorts for clinical research. Because of this, most research is based on adult oncology methods or studies that don't fully account for

the children's distinct biological behavior and therapeutic responses. There aren't many effective treatment plans designed for younger kids as a result of the dearth of evidence from pediatric-specific clinical trials. Children may thus receive subpar care or treatment regimens that are based on less pertinent adult research, which may result in insufficient tumor control or a higher chance of adverse effects. To close this gap and enhance evidence-based treatment procedures for pediatric ocular malignancies, multicenter partnerships and pediatric oncology trials are crucial.[38]

8.3. Treatment-related toxicity

One of the key concerns in the treatment of juvenile ocular malignancies is treatment-related toxicity. Radiation treatments and chemotherapy have been shown to be successful in reducing tumor growth, but they can have serious long-term adverse consequences, particularly in young patients whose bodies and brains are still developing. Systemic toxicity from chemotherapy agents can result in organ damage and a higher chance of developing secondary cancers. Both chemotherapy and radiation can cause ocular adverse effects that might cause irreversible vision loss, including cataract formation, retinal toxicity, and optic neuropathy. Additionally, radiation therapy entails a long-term risk of development anomalies, especially in the developing orbital structures, and an increased chance of additional cancers, even if it may be beneficial in some circumstances, such as retinoblastoma. In pediatric ocular oncology, minimizing treatment-related toxicity while maintaining effective tumor control is a never-ending challenge. Targeted therapies and molecular profiling, two aspects of personalized medicine, may open up new possibilities for minimizing these side effects while preserving high tumor control rates. To improve these strategies and guarantee the security of long-term survivors, more study is necessary.[42]

9. Future Directions

9.1. Personalized medicine

In pediatric ocular oncology, personalized medicine which adjusts medical care to each patient's unique characteristics is quickly becoming a key tactic. More accurate identification of genetic mutations, tumor markers, and molecular pathways implicated in ocular tumors specifically retinoblastoma and ocular melanoma has been made possible by developments in genomics and molecular diagnostics. Clinicians can anticipate treatment outcomes, reduce toxicity, and gain a deeper understanding of the tumor's distinct biology by employing thorough genomic profiling. Targeted therapies, which concentrate on particular molecular targets or genetic mutations, are examples of personalized therapy approaches that hold promise for enhancing treatment outcomes while maintaining ocular function. Continued pharmacogenomics research will improve customized dosage and lessen side effects in children.[43]

9.2. AI and machine learning

Artificial intelligence (AI) and machine learning (ML) technologies are poised to revolutionize the diagnosis, treatment planning, and follow-up care for pediatric ocular tumors. Large datasets from imaging modalities like optical coherence tomography (OCT), ultrasound, and magnetic resonance imaging (MRI) can be analyzed by AI-powered algorithms to find subtle patterns that human observers might overlook. Early detection is made possible by these tools, which is essential for enhancing prognosis. Additionally, machine learning models can assist in predicting treatment responses, personalizing care strategies, and monitoring for recurrence. Integration of AI with molecular data holds promise for discovering new biomarkers and therapeutic targets, creating a comprehensive approach to the diagnosis and management of ocular tumors.[44,45]

9.3. Multicenter registries and international collaborations

Given the rarity of pediatric ocular tumors, multicenter registries and international collaborations are essential for advancing research and improving patient outcomes. Such collaborations enable the pooling of patient data from diverse populations, fostering robust, large-scale studies that are crucial for understanding rare tumor types, evaluating treatment protocols, and developing evidence-based guidelines. Global networks can also facilitate the sharing of novel therapeutic insights, best practices, and innovative treatment modalities, fostering a collaborative approach to tackling pediatric ocular cancers. These efforts provide an opportunity to standardize care across regions, ensuring that children, regardless of geographic location, have access to the most advanced and equitable treatment options.[46]

9.4. Pediatric-specific drug development

Pediatric-specific drug development remains a critical frontier in the treatment of ocular tumors. The pathophysiology of pediatric cancers differs significantly from that of adults, and therapies effective in adult populations may not be as safe or effective for children. The unique biological characteristics of ocular tumors in children require drugs that can target their specific molecular and cellular features while minimizing long-term toxicity. The pediatric ocular oncology must prioritize the development of treatments that preserve vision and improve quality of life. Initiatives focused on pediatric drug development, including clinical trials designed specifically for children, are crucial for addressing these unmet needs. As regulatory frameworks evolve to facilitate pediatric drug trials, there is growing hope for new, effective, and safer treatment options for pediatric patients with ocular tumors.[47,48]

10. Conclusion

Pediatric ocular tumors, although rare, present significant diagnostic and therapeutic challenges that necessitate an integrated, multidisciplinary approach. Advances in imaging

technologies, molecular diagnostics, and treatment modalities have markedly improved the outcomes for conditions such as retinoblastoma, orbital rhabdomyosarcoma, and medulloepithelioma. However, these tumors remain a substantial cause of morbidity and mortality, emphasizing the need for continued innovation in both treatment and diagnostic strategies. The importance of early diagnosis cannot be overstated, as it is directly correlated with improved prognosis and preservation of vision and quality of life. As such, efforts should be concentrated on enhancing early detection techniques, refining risk stratification, and minimizing treatment-related toxicity. Looking toward the future, innovation in pediatric ocular oncology will depend on the development of personalized medicine, novel targeted therapies, and the integration of artificial intelligence for diagnostic precision. Moreover, collaboration across international research networks and pediatric oncology registries will be vital in improving treatment protocols, as these rare conditions require large, diverse data sets for evidence-based guidance. Ultimately, the future vision for pediatric ocular oncology should center on preserving vision and life with minimally invasive interventions, while ensuring that long-term survivorship is coupled with reduced risks of second malignancies and quality of life issues. The synergy of technological advancements and collaborative research will shape the trajectory of care for affected children in the years to come.

11. Source of Funding

None.

12. Conflict of Interest

None.

References

1. Castillo-Jr BV, Kaufman L. Pediatric tumors of the eye and orbit. *Pediatr Clin North Am*. 2003;50(1):149–72.
2. Rao AA, Naheedy JH, Chen JY, Robbins SL, Ramkumar HL. A clinical update and radiologic review of pediatric orbital and ocular tumors. *J Oncol*. 2013;2013:975908.
3. Suleiman D, Iliyasu Y, Ahmed S, Liman A. Histopathologic spectrum of paediatric eye and ocular adnexal tumours: A 10-year review from a referral centre in Nigeria. *Niger J Clin Pract*. 2020;23(5):654–9.
4. Jurdy L, Merks JH, Pieters BR, Mourits MP, Kloos RJHM, Strackee SD, et al. Orbital rhabdomyosarcomas: A review. *Saudi J Ophthalmol*. 2013;27(3):167–75.
5. Kaur K, Patel BC. Retinoblastoma. [Updated 2025 Feb 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
6. Byroju VV, Nadukkandy AS, Cordani M, Kumar LD. Retinoblastoma: present scenario and future challenges. *Cell Commun Signal*. 2023;21(1):226.
7. Kajal S, Cui D, Winters R. Malignant Orbital Tumors. [Updated 2024 Apr 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
8. Balmer A, Munier F. Differential diagnosis of leukocoria and strabismus, first presenting signs of retinoblastoma. *Clin Ophthalmol*. 2007;1(4):431–9.
9. Correa ZM, Berry JL. Review of retinoblastoma. American Academy of Ophthalmology. 2016. https://www.aao.org/education/disease-review/review-of-retinoblastoma
10. Joshi RS, Surwade T, Rasal A. Rhabdomyosarcoma masquerading as orbital cellulitis. *Indian J Ophthalmol*. 2022;70(7):2739–41.
11. Shah PK, Meeralakshmi P, Shanthi R, Saravanan VR, Kalpana N, Narendran V. Pigmented ciliary body medulloepithelioma in a newborn infant. *Oman J Ophthalmol*. 2017;10(3):257–8.
12. Patel DR, Blair K, Patel BC. Ocular Melanoma. [Updated 2024 May 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
13. Salma M, Salma EA, Yahya EH, Samia S, Ihssan HH, Sabrine D, et al. Orbital dermoid cyst in children: A case report. *Radiol Case Rep*. 2024;20(1):140-4.
14. Koka K, Zeppieri M, Patel BC. Periocular Capillary Infantile Hemangiomas. [Updated 2024 Dec 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538249/
15. Das S, Dey MK, Devireddy R, Gartia MR. Biomarkers in Cancer Detection, Diagnosis, and Prognosis. *Sensors*. 2023;24(1):37.
16. Kadakia A, Zhang J, Yao X, Zhou Q, Heiferman MJ. Ultrasound in ocular oncology: Technical advances, clinical applications, and limitations. *Exp Biol Med (Maywood)*. 2023;248(5):371–79.
17. De Graaf P, Göricke S, Rodjan F, Galluzzi P, Maeder P, Castelijns JA, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. *Pediatr Radiol*. 2012;42(1):2–14.
18. Spencer MA, Welch RJ, Shields CL. Hand-held Optical Coherence Tomography Monitoring of Submillimeter Retinoblastoma Treated with Indocyanine Green-enhanced Transpupillary Therapy. *Middle East Afr J Ophthalmol*. 2018;25(2):108–10.
19. Lohmann DR, Gallie BL. Retinoblastoma. 2000 Jul 18 [Updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.
20. Polski A, Xu L, Prabakar RK, et al. Cell-Free DNA Tumor Fraction in the Aqueous Humor Is Associated With Therapeutic Response in Retinoblastoma Patients. *Transl Vis Sci Technol*. 2020;9(10):30.
21. Milman T, Grossniklaus HE, Goldman-Levy G, Kim JW, Shah R, Jubran R, et al. The 5th Edition of the World Health Organization Classification of Tumours of the Eye and Orbit. *Ocul Oncol Pathol*. 2023;9(3-4):71-95.
22. Abbas, Z.; Rehman, S. An overview of cancer treatment modalities. In InTech eBooks; 2018. https://doi.org/10.5772/intechopen.76558.
23. Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: A 2020 review. *Indian J Ophthalmol*. 2020;68(11):2356–65.
24. Warda O, Naeem Z, Roelofs KA, Sagoo MS, Reddy MA. Retinoblastoma and vision. *Eye (Lond)*. 2023;37(5):797-808.
25. Lorigan P, Lee SM, Betticher D, Woodhead M, Weir D, Hanley S, et al. Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer. *Semin Oncol*. 1995;22(3 Suppl 7):32-41.
26. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. *Arch Ophthalmol*. 2012;130(10):1268–71.
27. Berry JL, Kogachi K, Murphree AL, Jubran R, Kim JW. A Review of Recurrent Retinoblastoma: Children's Hospital Los Angeles Classification and Treatment Guidelines. *Int Ophthalmol Clin*. 2019;59(2):65-75.
28. Mannor GE, Rose GE, Plowman PN, Kingston J, Wright JE, Vardy SJ. Multidisciplinary management of refractory orbital rhabdomyosarcoma. *Ophthalmology*. 1997;104(7):1198–201.
29. Chisholm J, Mandeville H, Adams M, Minard-Collin V, Rogers T, Kelsey A, et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). *Cancers (Basel)*. 2024;16(5):998.
30. Purohit BS, Vargas MI, Ailianou A, Merlini L, Poletti PA, Platon A, et al. Orbital tumours and tumour-like lesions: exploring the

armamentarium of multiparametric imaging. *Insights Imaging*. 2016;7(1):43-68.
31. Frankart AJ, Breneman JC, Pater LE. Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma. *Cancers (Basel)*. 2021;13(14):3567.
32. Pareek A, Kumar D, Pareek A, Gupta MM, Jeandet P, Ratan Y, et al. Retinoblastoma: An update on genetic origin, classification, conventional to next-generation treatment strategies. *Heliyon*. 2024;10(12):e32844.
33. Schaiquevich P, Francis JH, Cancela MB, Carcaboso AM, Chantada GL, Abramson DH. Treatment of Retinoblastoma: What Is the Latest and What Is the Future. *Front Oncol*. 2022;12:822330.
34. Basudan AM. The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clin Pract. 2022;13(1):22-40.
35. Shi H, He X, Yang Z, Liao Q, Ruan J, Ge S, et al. The Use of rAAV2-RB1-Mediated Gene Therapy in Retinoblastoma. *Invest Ophthalmol Vis Sci*. 2023;64(15):31.
36. Wu KY, Ashkar S, Jain S, Marchand M, Tran SD. Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma. *Polymers*. 2023;15(6):1373.
37. Kaliki S, Vempuluru VS, Ghose N, Patil G, Viriyala R, Dhara KK. Artificial intelligence and machine learning in ocular oncology: Retinoblastoma. *Indian J Ophthalmol*. 2023;71(2):424–30.
38. Hameed S, Yu AC, Almadani B, Abualkhair S, Ahmad K, Zauli G. Genetic Risk Factors and Clinical Outcomes in Childhood Eye Cancers: A Review. *Genes*. 202415(3):276.
39. Zhao J, Feng Z, Leung G, Gallie BL. Retinoblastoma Survival Following Primary Enucleation by AJCC Staging. Cancers. 2021;13(24):6240.
40. Kaur K, Patel BC. Retinoblastoma. [Updated 2025 Feb 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
41. Hutchinson AK, Morse CL, Hercinovic A, Cruz OA, Sprunger DT, Repka MX, et al. Pediatric Eye Evaluations Preferred Practice Pattern. *Ophthalmology*. 2023;130(3):P222–70.
42. Schaiquevich P, Francis JH, Cancela MB, Carcaboso AM, Chantada GL, Abramson DH. Treatment of Retinoblastoma: What Is the Latest and What Is the Future. *Front Oncol*. 2022;12:822330.
43. Kulbay M, Tuli N, Mazza M, Jaffer A, Juntipwong S, Marcotte E, et al. Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances. *Biomedicines*. 2025;13(1):108.
44. Tong Y, Lu W, Yu Y, Shen Y. Application of machine learning in ophthalmic imaging modalities. *Eye Vis (Lond)*. 2020;7:22.
45. Mane DV, Khuspe PR. Machine learning in ocular oncology and oculoplasty: Transforming diagnosis and treatment. *IP Int J Ocul Oncol Oculoplasty*. 2024;10(4):196–207.
46. Masoomian B, Dalvin LA, Riazi-Esfahani H, Ghassemi F, Azizkhani M, Mirghorbani M, et al. Pediatric ocular melanoma: a collaborative multicenter study and meta-analysis. *J AAPOS*. 2023;27(6):316–24.
47. Domingues C, Jarak I, Veiga F, Dourado M, Figueiras A. Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies. *Pharmaceutics*. 2023;15(10):2431.
48. Houghton PJ, Kurmasheva RT. Challenges and Opportunities for Childhood Cancer Drug Development. *Pharmacol Rev.* 2019;71(4):671–97.

Cite this article: Khuspe P, Phade S, Kakade S, Inamdar P, Kokate K. Pediatric ocular tumors: Current perspectives and future directions. *IP Int J Ocul Oncol Oculoplasty*. 2025;11(2):60-69.